Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Income from Continuing Operations (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Income from Continuing Operations for 7 consecutive years, with 97986000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 21.25% to 97986000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 349768000.0 through Dec 2025, down 33.56% year-over-year, with the annual reading at 349769000.0 for FY2025, 33.56% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 97986000.0 at Kymera Therapeutics, down from 92619000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 13193000.0 in Q1 2021, with the low at 97986000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 51975650.0, with a median of 45149500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations soared 49.95% in 2023, then tumbled 317.34% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 34045000.0 in 2021, then dropped by 13.64% to 38689000.0 in 2022, then soared by 49.95% to 19364000.0 in 2023, then crashed by 317.34% to 80814000.0 in 2024, then dropped by 21.25% to 97986000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 97986000.0, 92619000.0, and 84665000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.